Huakan Medical Profit Collapses 87%, Scraps Dividend

Edgen Stock

·Mar 30 2026, 01:43

Share to

Share to

Copy link

Key Takeaways

Huakan Medical reported a severe downturn for its 2025 fiscal year, with net profit plummeting 86.6% to RMB 34.93 million and revenue declining 10.8%. In response to the weak performance, the company announced it will not distribute a final dividend, signaling financial strain and likely triggering a negative market reaction.

Profit Downfall: Net profit for the year ended December 2025 fell by 86.6% year-over-year to RMB 34.933 million.
Revenue Shrinks: Full-year revenue contracted by 10.8% to RMB 2.821 billion, indicating a drop in operational performance.
Dividend Canceled: The company will not issue a final dividend, a decision that will likely concern investors about its financial health and cash flow.

Profit Plummets 86.6% on Weaker Revenue

Huakan Medical (01931.HK) disclosed a steep decline in profitability for the full year ending last December, signaling significant operational headwinds. The company's net profit collapsed by 86.6% year-over-year to RMB 34.933 million. This sharp drop in earnings was driven by a 10.8% contraction in annual revenue, which fell to RMB 2.821 billion. The poor performance resulted in earnings per share (EPS) of just RMB 0.0216 for the period.

Company Halts Dividend Payouts

In a move reflecting its deteriorating financial position, Huakan Medical's board announced it will not distribute a final dividend for the year. This decision is a direct consequence of the profit collapse and represents a significant blow to income-oriented shareholders. The cancellation of the dividend suggests management is prioritizing cash preservation, raising concerns among investors about the company's near-term operational stability and its outlook for a recovery.